• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    60 Biggest Movers From Yesterday

    1/11/22 4:52:58 AM ET
    $AACG
    $ADMP
    $APR
    $APYX
    Other Consumer Services
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AACG alert in real time by email

    Gainers

    • Bone Biologics Corporation (NASDAQ:BBLG) shares surged 57.1% to close at $5.39 on Monday.
    • Zynga Inc. (NASDAQ:ZNGA) rose 40.7% to settle at $8.44 after the company announced it will be acquired by Take-Two Interactive Software in a cash and stock transaction valued at $9.86 per Zynga share, representing a total enterprise value of approximately $12.7 billion.
    • Molecular Partners AG (NASDAQ:MOLN) surged 30.5% to settle at $21.50 after the company, and Novartis, reported topline data from the Phase 2 study for ensovibep, a DARPin antiviral therapeutic for COVID-19.
    • Reliance Global Group, Inc. (NASDAQ:RELI) climbed 28.9% to close at $7.86. Reliance Global Group, last month, announced pricing of $20.0 million private placement with institutional investors.
    • RxSight, Inc. (NASDAQ:RXST) gained 28.2% to settle at $11.50 after the company late Sunday issued preliminary Q4 and FY21 guidance above estimates.
    • BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) jumped 27.9% to close at $14.78 after the company announced preliminary, unaudited ORLADEYO revenue for Q4 and FY21 and provided new guidance for full year 2022 ORLADEYO net revenue and expected peak ORLADEYO sales.
    • iRhythm Technologies, Inc. (NASDAQ:IRTC) surged 27.6% to settle at $130.04.
    • Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) rose 27% to close at $0.73 after the company announced the submission of a Fast Track Application to the FDA for Tempol for the treatment and prevention of COVID-19.
    • Apria, Inc. (NASDAQ:APR) shares gained 26.1% to close at $37.48. Owens & Minor agreed to acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion.
    • Discovery, Inc. (NASDAQ:DISCB) climbed 25.5% to close at $44.50. The company, along with AT&T, recently won a favorable ruling from the Internal Revenue Service for the planned merger between the company and AT&T's WarnerMedia entertainment business.
    • Pluristem Therapeutics Inc. (NASDAQ:PSTI) jumped 24.5% to close at $1.83. Pluristem Therapeutics and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry.
    • Olink Holding AB (NASDAQ:OLK) rose 23.8% to settle at $14.46. Olink said it sees Q4 sales of $43.2 million to $43.7 million and expects FY21 sales of $94.5 million to $95 million.
    • Biofrontera Inc. (NASDAQ:BFRI) gained 22% to close at $6.26.
    • Immunic, Inc. (NASDAQ:IMUX) jumped 19.2% to settle at $11.49.
    • Apyx Medical Corporation (NASDAQ:APYX) shares rose 19.1% to settle at $12.98. Apyx Medical Corporation sees preliminary Q4 sales of $16.3 million to $16.8 million, up 42% year over year.
    • CareDx, Inc (NASDAQ:CDNA) shares jumped 18.5% to close at $46.29 after the company issued strong sales forecast.
    • G Medical Innovations Holdings Ltd (NASDAQ:GMVD) jumped 17.3% to close at $2.64. McDade Products, LLC joined forces with G Medical Tests and Services to provide U.S. retailers with millions of COVID-19 at-home PCR test kits.
    • Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) gained 16.8% to settle at $2.50.
    • Lucira Health, Inc. (NASDAQ:LHDX) rose 15.6% to close at $8.29 after the company issued strong sales forecast for the fourth quarter.
    • Treace Medical Concepts, Inc. (NASDAQ:TMCI) gained 14.9% to close at $20.25. Treace Medical Concepts sees Q4 sales of $33.100 million to $33.400 million.
    • Odonate Therapeutics, Inc. (NASDAQ:ODT) surged 14.7% to settle at $1.25. Odonate Therapeutics recently received notice from The Nasdaq Stock Market that the continued listing of its securities is no longer warranted.
    • Century Therapeutics, Inc. (NASDAQ:IPSC) gained 14.5% to close at $15.14. Century Therapeutics and Bristol Myers Squibb have announced a research collaboration and license agreement for up to four induced pluripotent stem cell (iPSC) programs for hematologic malignancies and solid tumors.
    • Venus Concept Inc. (NASDAQ:VERO) jumped 13.8% to settle at $1.82. Venus Concept sees Q4 sales of $32 million to $33 million.
    • Tilray, Inc. (NASDAQ:TLRY) gained 13.6% to close at $7.29 after the company announced fiscal second-quarter 2022 financial results showing revenue increased year-over-year and the company reached profitability.
    • Immix Biopharma, Inc. (NASDAQ:IMMX) rose 12.7% to close at $6.02.
    • Arco Platform Limited (NASDAQ:ARCE) shares gained 10.1% to settle at $20.55.
    • Jazz Pharmaceuticals plc (NASDAQ:JAZZ) jumped 9% to settle at $146.49 after the company announced its Vision 2025 expectations.

     

    Check out these big penny stock gainers and losers

    Losers

    • TDH Holdings, Inc. (NASDAQ:PETZ) shares tumbled 81.9% to close at $0.74 on Monday. TDH Holdings, last month, reported H1 revenue of $130,000.
    • OneSmart International Education Group Limited (NYSE:ONE) fell 33.1% to close at $0.1941 after gaining more than 5% on Friday.
    • Kidpik Corp. (NASDAQ:PIK) fell 27.5% to settle at $4.75. Kidpik, last month, posted a Q3 loss of $0.22 per share.
    • Torrid Holdings Inc. (NYSE:CURV) fell 22.4% to close at $8.20 after the company lowered its Q4 revenue guidance.
    • Rapid Micro Biosystems, Inc. (NASDAQ:RPID) fell 21.2% to close at $7.20. Rapid Micro Biosystems said it expects Q4 total revenue of between $4.7 and $5.2 million.
    • China HGS Real Estate Inc. (NASDAQ:HGSH) fell 21% to close at $2.75 after jumping over 57% on Friday.
    • Marin Software Incorporated (NASDAQ:MRIN) dipped 19% to close at $3.67. Marin Software shares jumped 31% on Friday after the company announced an integration with Amazon Ads' demand-side platform.
    • eMagin Corporation (NYSE:EMAN) fell 18.9% to settle at $1.46.
    • Elite Education Group International Limited (NASDAQ:EEIQ) tumbled 18.4% to close at $2.40.
    • Bird Global, Inc. (NYSE:BRDS) fell 17.6% to close at $6.81.
    • Excellon Resources Inc. (NYSE:EXN) dropped 17.5% to settle at $0.7706.
    • Marpai, Inc. (NASDAQ:MRAI) shares dropped 17.2% to close at $2.92.
    • Amicus Therapeutics, Inc. (NASDAQ:FOLD) fell 17.2% to close at $9.45. Amicus Therapeutics said it sees FY21 Galafold sales of $306 million.
    • ATA Creativity Global (NASDAQ:AACG) fell 17.1% to settle at $2.19 after jumping more than 33% on Friday.
    • The Beauty Health Company (NASDAQ:SKIN) dropped 16.7% to close at $18.46. Beauty Health expects FY21 sales around the high end of prior guidance of $245 million to $255 million.
    • Pixelworks, Inc. (NASDAQ:PXLW) fell 16.6% to close at $3.43.
    • Citi Trends, Inc. (NASDAQ:CTRN) shares fell 16.3% to close at $67.89. Citi Trends reported 2021 holiday sales results and updated long-term strategic plan.
    • Nurix Therapeutics, Inc. (NASDAQ:NRIX) tumbled 15.9% to close at $23.27.
    • RAPT Therapeutics, Inc. (NASDAQ:RAPT) dropped 15.8% to settle at $32.89.
    • Energy Focus, Inc. (NASDAQ:EFOI) fell 15.7% to settle at $2.89.
    • Digital Brands Group, Inc. (NASDAQ:DBGI) dropped 15.2% to close at $1.96.
    • Hour Loop, Inc. (NASDAQ:HOUR) declined 14.8% to close at $6.81. The company’s stock jumped around 100% on Friday after the company priced its IPO at $4 per share.
    • Eliem Therapeutics, Inc. (NASDAQ:ELYM) shares fell 14.7% to close at $9.43.
    • Take-Two Interactive Software, Inc. (NASDAQ:TTWO) dropped 13.1% to close at $142.99 after the company announced it will acquire all of the outstanding shares of Zynga in a cash and stock transaction valued at $9.861 per Zynga share, with a total enterprise value of approximately $12.7 billion.
    • Team, Inc. (NYSE:TISI) fell 12.8% to close at $1.02.
    • Zhangmen Education Inc. (NYSE:ZME) fell 12.5% to close at $1.88.
    • CinCor Pharma, Inc. (NASDAQ:CINC) fell 11.7% to settle at $14.13. The company, on Friday, priced its IPO at $16 per share.
    • Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) fell 11.1% to close at $1.85.
    • Cyngn Inc. (NASDAQ:CYN) fell 10.5% to close at $3.25. Cyngn said Global Logistics and Fulfillment LLC has engaged the company as its exclusive autonomous vehicle solutions provider.
    • Vigil Neuroscience, Inc. (NASDAQ:VIGL) fell 9.8% to settle at $11.41. The company, on Friday, priced its IPO at $14 per share.
    • Arcadia Biosciences, Inc. (NASDAQ:RKDA) shares fell 7.9% to settle at $1.05 after climbing around 12% on Friday.
    • GameStop Corp. (NYSE:GME) dropped 6.7% to close at $131.15 amid overall market weakness following a rise in yields as well as continued Fed tapering concerns for 2022.
    • Fangdd Network Group Ltd. (NASDAQ:DUO) fell 6.1% to close at $0.3493. FangDD, on Friday, received Nasdaq notice regarding minimum bid requirements.
    Get the next $AACG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AACG
    $ADMP
    $APR
    $APYX

    CompanyDatePrice TargetRatingAnalyst
    Immunic Inc.
    $IMUX
    4/17/2026$2.50Buy
    Stifel
    Immunic Inc.
    $IMUX
    4/15/2026Buy → Hold
    D. Boral Capital
    Jazz Pharmaceuticals plc
    $JAZZ
    4/10/2026$227.00Outperform
    Raymond James
    Tilray Brands Inc.
    $TLRY
    4/3/2026$10.00Neutral → Buy
    Roth Capital
    Tilray Brands Inc.
    $TLRY
    4/2/2026$10.00Neutral → Buy
    Roth Capital
    Immix Biopharma Inc.
    $IMMX
    3/25/2026$20.00Overweight
    Morgan Stanley
    Immunic Inc.
    $IMUX
    3/24/2026$7.00Buy
    Guggenheim
    Apyx Medical Corporation
    $APYX
    3/11/2026$6.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $AACG
    $ADMP
    $APR
    $APYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Immunic with a new price target

    Stifel initiated coverage of Immunic with a rating of Buy and set a new price target of $2.50

    4/17/26 8:12:09 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic downgraded by D. Boral Capital

    D. Boral Capital downgraded Immunic from Buy to Hold

    4/15/26 7:47:45 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Jazz Pharma with a new price target

    Raymond James resumed coverage of Jazz Pharma with a rating of Outperform and set a new price target of $227.00

    4/10/26 12:21:53 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AACG
    $ADMP
    $APR
    $APYX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Treace to Report First Quarter 2026 Financial Results on May 8, 2026

    PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the first quarter 2026 before the start of trading on Friday, May 8, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and ar

    4/24/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries, today issued a statement applauding President Donald Trump's actions leading to rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act - a defining inflection point that represents a fundamental shift in U.S. drug policy, unlocking significant opportunities for medical cannabis clinical research, patient access, and industry standardization. The action represents the most consequential federal cannabis

    4/23/26 8:53:52 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Immunic, Inc. Announces 1-for-10 Reverse Stock Split

    NEW YORK, April 23, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the "Company" or "Immunic"), today announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on April 27, 2026.Immunic's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "IMUX" and will begin trading on a reverse stock split-adjusted basis at the opening of the Nasdaq Capital Market on April 27, 2026. The new CUSIP number for the split-adjusted common stock will be 4525EP200.At the Company's special me

    4/23/26 8:00:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AACG
    $ADMP
    $APR
    $APYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cheng Lawrence bought $114,368 worth of shares (5,000 units at $22.87) (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/26/26 9:06:47 AM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    President, CEO and Chairman Cohen Ryan bought $21,359,200 worth of shares (1,000,000 units at $21.36), increasing direct ownership by 3% to 38,347,842 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/22/26 4:02:03 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    Director Attal Alain bought $259,577 worth of shares (12,000 units at $21.63), increasing direct ownership by 2% to 596,464 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/21/26 6:32:09 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    $AACG
    $ADMP
    $APR
    $APYX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.

    SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    4/24/26 9:28:23 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by SkinHealth Systems Inc.

    DEF 14A - SkinHealth Systems Inc. (0001818093) (Filer)

    4/24/26 4:10:19 PM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 10-K/A filed by Jazz Pharmaceuticals plc

    10-K/A - Jazz Pharmaceuticals plc (0001232524) (Filer)

    4/24/26 4:09:04 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AACG
    $ADMP
    $APR
    $APYX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZIMHI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer

    10/18/21 11:55:40 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

    For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl

    8/12/21 4:25:43 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SYMJEPI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling

    6/30/21 5:11:48 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AACG
    $ADMP
    $APR
    $APYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Wu Zhenyu converted options into 6,250 units of Ordinary Shares, increasing direct ownership by 8% to 86,681 units (SEC Form 4)

    4 - EpicQuest Education Group International Ltd (0001781397) (Issuer)

    4/24/26 4:30:16 PM ET
    $EEIQ
    Other Consumer Services
    Real Estate

    Chief Executive Officer Zhang Jianbo converted options into 7,813 units of Ordinary Shares, increasing direct ownership by 5% to 175,482 units (SEC Form 4)

    4 - EpicQuest Education Group International Ltd (0001781397) (Issuer)

    4/24/26 4:30:14 PM ET
    $EEIQ
    Other Consumer Services
    Real Estate

    SEC Form 4 filed by Seipel Kenneth Duane

    4 - Citi Trends Inc (0001318484) (Issuer)

    4/22/26 8:46:41 PM ET
    $CTRN
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $AACG
    $ADMP
    $APR
    $APYX
    Financials

    Live finance-specific insights

    View All

    Treace to Report First Quarter 2026 Financial Results on May 8, 2026

    PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the first quarter 2026 before the start of trading on Friday, May 8, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and ar

    4/24/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

    CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the first quarter of fiscal year 2026 will be released before markets open on Thursday, May 7th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 7th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81537.

    4/23/26 8:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Take-Two Interactive Software, Inc. to Report Fourth Quarter and Fiscal Year 2026 Results on Thursday, May 21, 2026

    Take-Two Interactive Software, Inc. (NASDAQ:TTWO) today announced that it plans to report financial results for its fourth quarter and fiscal year 2026, ended March 31, 2026, after the market close on Thursday, May 21, 2026. The Company plans to hold a conference call to discuss its results at 4:30 p.m. Eastern Time, which can be accessed by dialing (800) 715-9871 or (646) 307-1963 (conference ID: 9711440). A live, listen-only webcast and a replay of the call will be available at http://take2games.com/ir. About Take-Two Interactive Software Headquartered in New York City, Take-Two Interactive Software, Inc. is a leading developer, publisher, and marketer of interactive entertainment for

    4/23/26 8:00:00 AM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AACG
    $ADMP
    $APR
    $APYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fangdd Network Group Ltd.

    SC 13G - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:26:40 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Fangdd Network Group Ltd.

    SC 13G/A - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:24:27 PM ET
    $DUO
    Real Estate
    Finance

    SEC Form SC 13G filed by Torrid Holdings Inc.

    SC 13G - Torrid Holdings Inc. (0001792781) (Subject)

    12/12/24 6:06:52 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $AACG
    $ADMP
    $APR
    $APYX
    Leadership Updates

    Live Leadership Updates

    View All

    SkinHealth Systems Inc. Appoints Three New Independent Directors to Board

    LONG BEACH, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. ((formerly The Beauty Health Company, NASDAQ:SKIN), a global medical aesthetics company, today announced the appointment of three new independent directors to its Board of Directors (the "Board"): Mr. Kenneth Tripp, Dr. Sachin Shridharani, and Mr. E. Scott Beattie, each effective as of April 17, 2026. "These three appointments reflect exactly the kind of Board we are building at SkinHealth Systems – one that brings extensive operational expertise in medtech, deep clinical authority in aesthetics, and proven leadership in scaling iconic global consumer brands," said Brent Saunders, Chairman of SkinHealth Systems

    4/22/26 4:05:00 PM ET
    $SKIN
    Medical/Dental Instruments
    Health Care

    Nerdy Inc. Appoints Atul Bagga as Chief Financial Officer

    Nerdy Inc. (NYSE:NRDY), a leading platform for delivering live online learning, today announced the appointment of Atul Bagga as Chief Financial Officer, effective April 6, 2026. "Atul is a disciplined and strategic financial leader with deep experience scaling high-growth technology organizations and driving operational excellence," said Chuck Cohn, Founder, Chairman and Chief Executive Officer of Nerdy. "As we enter our next phase of growth from a position of strength, we remain focused on disciplined execution, continued margin expansion, and durable value creation. Atul's background will be instrumental in building on the strong foundation we have established." In this role, Mr. Bag

    4/6/26 9:00:00 AM ET
    $JLL
    $NRDY
    $ZNGA
    Real Estate
    Finance
    Other Consumer Services
    EDP Services

    BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

    — Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval —  RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer. Building on the commercial success of ORLADEYO® and the recent acquisition of Astria Therapeutics and the navenibart program, BioCryst is entering a new phase of execution in its strategy to build value through development and commercialization of rare disease therapies. Dr. Menon joins BioCryst from Alnylam Pharmaceuticals, where he served as Chief Devel

    4/6/26 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AACG
    $ADMP
    $APR
    $APYX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care